DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-11 |
2024-09 |
-0.16 |
N/A |
N/A |
N/A |
2024-08-07 |
2024-06 |
-0.16 |
-0.13 |
0.03 |
18.75% |
2024-05-08 |
2024-03 |
-0.16 |
-0.14 |
0.02 |
12.50% |
2024-05-08 |
2024-03 |
-0.16 |
N/A |
N/A |
N/A |
2024-03-19 |
2023-12 |
-0.14 |
N/A |
N/A |
N/A |
2024-03-19 |
2023-12 |
-0.14 |
-0.14 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-06-21 |
Oppenheimer |
Upgrade |
Perform |
Outperform |
2022-07-06 |
Oppenheimer |
Downgrade |
Outperform |
Perform |
2022-07-06 |
Craig-Hallum |
Upgrade |
|
Buy |
2022-07-06 |
Lake Street |
Upgrade |
|
Buy |
2021-06-29 |
Roth Capital |
Upgrade |
|
Buy |
2021-04-07 |
Oppenheimer |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-01 |
GIUFFRE RANDALL MICHAEL |
Director |
411.19K |
Stock Award(Grant) |
2023-06-22 |
KELLEN SCOTT |
Chief Financial Officer |
32.29K |
Purchase |
2024-01-01 |
KUNTZ RICHARD P |
Director |
14.29K |
Stock Award(Grant) |
2024-01-01 |
PARSONS JAMES T CPA |
Director |
59.94K |
Stock Award(Grant) |
2023-06-22 |
PAULS DIETRICH JOHN |
Chief Executive Officer |
68.59K |
Purchase |
2024-01-01 |
PILNIK RICHARD D |
Director |
278.60K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Cooperman, Leon G. |
875.99K |
3.78M |
2.31% |
2023-06-29 |
Vanguard Group Inc |
782.99K |
3.38M |
2.06% |
2023-06-29 |
Paragon Associates & Paragon Associates Ii Joint Venture |
325.00K |
1.40M |
0.86% |
2023-06-29 |
Bleichroeder LP |
294.12K |
1.27M |
0.78% |
2023-06-29 |
EAM Investors, LLC |
270.42K |
1.17M |
0.71% |
2023-06-29 |
Jacob Asset Management of New York LLC |
198.73K |
858.51K |
0.52% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
506.27K |
2.19M |
1.33% |
2023-06-29 |
Vanguard Extended Market Index Fund |
228.62K |
987.64K |
0.60% |
2023-08-30 |
Jacob Discovery Fd |
178.73K |
527.25K |
0.47% |
2023-05-30 |
Fidelity Extended Market Index Fund |
82.67K |
225.69K |
0.22% |
2023-08-30 |
iShares Micro Cap ETF |
53.50K |
157.83K |
0.14% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
42.74K |
116.68K |
0.11% |
Split |
Date |
1 : 20 |
2018-11-15 |